- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Current Considerations in Managing Hyperhidrosis
Shawn Davis, PharmD: Hyperhidrosis is excessive sweating. It can happen on any part of the body—the hands, armpits, back. A lot of patients don’t really talk about it, because many people don’t think that it’s a real disease. That being said, the managed care community hasn’t really taken on hyperhidrosis or thought a lot about it, and there aren’t many good treatments for it.
Today, there are antiperspirants and some other over-the-counter options. Some of the prescription medications have been out on the market for 20-plus years, and they don’t really have good usage in hyperhidrosis. Allowing the patient to actually have something that’s going to be useful is going to be a breakthrough in therapy for them.
I believe that glycopyrronium tosylate will be the first cutting-edge medication that’s going to be approved by FDA that payers will take a hard look at. Payers will be able to identify patients who really need the medication and can ultimately find coverage for those who want and really need this medication in order to live the lifestyle that everyone else who doesn’t have hyperhidrosis lives today.
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More
